Results 21 to 30 of about 25,921 (246)

Suspected Suicide Attempt and Intentional Misuse Cases Aged 50+ Involving Amphetamine or Methylphenidate and Medical Outcomes: Associations with Co-Used Other Substances

Pharmacoepidemiology, 2023
Introduction: Given the increasing adult use of amphetamine and methylphenidate and their high misuse potential, we examined suspected suicide attempts and other intentional misuse and medical outcomes and their associations with co-used other substances
Namkee G. Choi, Bryan Y. Choi, S. David Baker   +2 more
doaj   +1 more source

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Respiratory Research, 2021
Background Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to ...
Manon Belhassen, Faustine Dalon, Maëva Nolin, Eric Van Ganse   +3 more
doaj   +1 more source

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Pharmacoepidemiology, 2023
Background: The coronavirus pandemic has led to the creation of clinical guidelines by a large number of professional medical communities. However, the quality and methodology of development of Russian clinical guidelines has been little studied.
Elena A. Baybulatova, Mikhail S. Chenkurov, Elina A. Korovyakova, Sergey K. Zyryanov, Liliya Eugenevna Ziganshina   +4 more
doaj   +1 more source

Clinical epidemiology and pharmacoepidemiology studies with real-world databases [PDF]

, 2022
Hospital-based registry data, including patients’ information collected by academic societies or government based research groups, were previously used for clinical research in Japan.
TANAKA-MIZUNO, Sachiko, MIZUNO, Kayoko, FUKASAWA, Toshiki, KAWAKAMI, Koji, YOSHIDA, Satomi, TAKEUCHI, Masato, NAKASHIMA, Masayuki   +6 more
core   +2 more sources

The Norwegian Society for Pharmacoepidemiology [PDF]

, 2021
The Norwegian Society for Pharmacoepidemiology (NFFE) is a multidisciplinary, nation-wide network of professionals involved in the field of pharmacoepidemiology.
Olsen, Kristine, Karlstad, Øystein, Lupattelli, Angela, Småbrekke, Lars, Øvrebust, Aina, Waaseth, Marit, Engeland, Anders   +6 more
core   +1 more source

Current status, and future prospects of pharmaco-epidemiology and post-marketing surveillance in Saudi Arabia: A review of literature

Saudi Pharmaceutical Journal, 2018
Background: Pharmacoepidemiology is the concept used for evaluating the impact of drugs among a large number of people in the post-marketing phase. The use of this concept makes it increasingly necessary to detect the recurrence of drug-related anomalies
Ashraf El-Metwally
doaj   +1 more source

Pharmacoepidemiology and Big Data Research

, 2023
Pharmacoepidemiology is a discipline that investigates the benefits, risks, and uses of medicines, biological agents, medical devices, and other medical interventions in large populations.
Man, Kenneth KC, Chan, Amy HY, Beyene, Kebede   +2 more
core   +1 more source

Needs and priority areas for building capacity for working with linked data in the Australian pharmacoepidemiology workforce

International Journal of Population Data Science, 2018
Introduction Linked data are increasingly used in pharmacoepidemiology studies to enhance value beyond that which can be achieve from stand-alone pharmaceutical data. The complexity of pharmaceutical data can make any linked data analysis challenging and
Derrick Lopez, Benjamin Daniels, Frank Sanfilippo, Sallie Pearson, Angelita Martini, David B Preen   +5 more
doaj   +1 more source

Birth Outcomes of Anticancer Drug Prescriptions during Pregnancy: A Case Series from a Japanese Claims Database

Pharmacoepidemiology, 2023
We aimed to evaluate the adverse birth outcomes of anticancer drug prescription during pregnancy using a Japanese claims database from 2005 to 2019.
Kentaro Tajima, Tomofumi Ishikawa, Masami Tsuchiya, Masafumi Kikuchi, Taku Obara, Nariyasu Mano   +5 more
doaj   +1 more source

Literature Review of Safety Event Reporting in Observational Studies: Challenges Extrapolating across Comparable Products

Pharmacoepidemiology, 2023
Nirmatrelvir/ritonavir (PAXLOVIDTM, Pfizer) is an anti-infective inhibiting CYP3A4 indicated for the treatment of COVID-19 in adults at increased risk of severe COVID-19. As a newly approved product, PAXLOVID has limited safety information regarding rare
Heather A. Ward, Bao-Anh Nguyen-Khoa, Robert Massouh   +2 more
doaj   +1 more source